
Hexagon Composites ASA (HXGCF) Q2 2026 Earnings Call Transcript
Hexagon Composites ASA (HXGCF) Q2 2026 Earnings Call Transcript
Latest financial and economic news and analysis

Hexagon Composites ASA (HXGCF) Q2 2026 Earnings Call Transcript

Pursuit Attractions and Hospitality, Inc. (PRSU) Q2 2026 Earnings Call Transcript

Morgan Advanced Materials plc (MCRUF) Q2 2026 Earnings Call Transcript

Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) and Marvell Technology (NASDAQ:MRVL) have cleared their most recent earnings, deepening the case for treating them as the market's preferred high beta alternatives to NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO).

ANI Pharmaceuticals is rated Buy at ~$80, with a 12-month fair value set at $95, as the current valuation undervalues 2027 earnings potential. 2026 results are depressed by upfront gout expansion costs and higher Corticotrophin royalties, but revenue and operating leverage from these investments are expected to materialize in 2027. Most 2026 Cortrophin growth is projected from established indications, not the new gout initiative, which is viewed as a 2027 upside driver.

Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption

Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - ATERRA Metals Inc. (CSE: ATC) (OTCQB: CSSCF) ("ATERRA" or the "Company") is pleased to announce that it has commenced preparation of the Company's maiden independent Mineral Resource Estimate ("MRE") for its Totora Cu/Au Project ("Totora" or the "Project"). The maiden MRE will define Totora's initial mineral inventory and establish the technical foundation for future economic studies.

ROSELAND, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, August 14, 2026, to discuss the company's financial results for the second quarter ended June 30, 2026, as well as the company's corporate progress and other developments.

CoreWeave (NASDAQ:CRWV) currently trades at $91.90 against a consensus analyst target of $138.03.

AppLovin Corporation delivered a robust quarter with 52.4% revenue growth and an 83.8% adjusted EBITDA margin, yet shares sold off sharply on modest headline misses. APP's balance sheet is strong, with $3B cash, $3.5B debt, and a 29x interest coverage ratio, supporting continued self-funded growth. Opening AXON Ads to self-serve expands TAM, targeting $7B in first-year ad spend from new verticals beyond gaming, including fintech and CTV.

Wall Street was predicted to see a mixed open on Thursday, as another batch of technology earnings undermines confidence and apparent progress towards an Iran deal raises fears of yet another false dawn. Dow Jones futures were up 57 points, or 0.1%, with the blue-chip index on course to build on the previous session's record close.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK's off-the-shelf allogeneic iNKT cell therapy, in acute lung injury.

The deal still faces substantial legal challenges in the U.S., where state attorneys general have sued to block the purchase.

Online secondhand marketplace ThredUp is adjusting its marketing tactics while navigating a “K-shaped” economy. The company reported quarterly earnings Wednesday (Aug. 5) showing revenues of $90.8 million, up 17% from the same quarter last year.

Initial agreement contemplates the purchase of up to 128 NVIDIA HGX B300 AI systems with an estimated aggregate hardware value of approximately $77 million based on current market pricing, subject to future purchase orders and customary conditions